A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.

Trial Details

NCT ID
NCT05307705
Phase
PHASE1
Sponsor
Eli Lilly and Company
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • LOXO-783
  • Fulvestrant
  • Imlunestrant
  • Abemaciclib
  • Anastrozole, Exemestane, or Letrozole
  • Paclitaxel
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Stanford, California, United States|37.42411,-122.16608
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Have advanced breast cancer or another solid tumor with the presence of a phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) H1047R mut…
  • Have adequate archival tumor tissue sample available or be approved by the Sponsor for enrollment if no tumor sample is available.
  • Have stopped all cancer treatment and have recovered from the major side effects
  • Have adequate organ function, as measured by blood tests

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →